These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1975416)

  • 1. Inhibitors to monoclonal antibody purified factor VIII.
    Bell BA; Kurczynski EM; Bergman G
    Lancet; 1990 Sep; 336(8715):638. PubMed ID: 1975416
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous infusion of monoclonal antibody-purified factor VIII.
    Weinstein RE; Bona RD; Rickles FR
    Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate.
    Lusher JM
    Lancet; 1990 Nov; 336(8725):1249-50. PubMed ID: 1978087
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors.
    Ingerslev J; Wallevik K
    Ann Hematol; 1991 Sep; 63(3):152-4. PubMed ID: 1932291
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
    Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of a premature infant with moderate haemophilia A using recombinant factor VIII.
    Gale RF; Hird MF; Colvin BT
    Haemophilia; 1998 Nov; 4(6):850-3. PubMed ID: 10028309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disappearance of FVIII inhibitors in a severe hemophilia A neonate after steroid treatment correlated with a cytokine shift toward a T-helper 2 pattern.
    Vianello F; Zanon E; Zerbinati P; Innella B; Girolami A
    Haematologica; 2000 Oct; 85(10):1114-5. PubMed ID: 11025617
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor VIII inhibitors. Potential for prevention of inhibitor formation by immune tolerance.
    Kaplan J; Genyea C; Secord E
    Semin Thromb Hemost; 2000; 26(2):173-8. PubMed ID: 10919410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.
    Lusher JM
    Ann Hematol; 1991 Sep; 63(3):138-41. PubMed ID: 1932288
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate.
    Berntorp E; Nilsson IM; Ljung R; Widell A
    Lancet; 1990 Jun; 335(8704):1531-2. PubMed ID: 1972463
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous infusion of highly purified factor VIII (Monoclate M).
    Flora S; Hambley H; Thumpston J; Clark J
    Am J Hematol; 1992 Jun; 40(2):157. PubMed ID: 1585918
    [No Abstract]   [Full Text] [Related]  

  • 12. Human factor VIII:C purified using monoclonal antibody to von Willebrand factor.
    Levine PH
    Semin Hematol; 1988 Apr; 25(2 Suppl 1):1-2. PubMed ID: 3133770
    [No Abstract]   [Full Text] [Related]  

  • 13. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
    J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended half-life factor VIII for immune tolerance induction in haemophilia.
    Malec LM; Journeycake J; Ragni MV
    Haemophilia; 2016 Nov; 22(6):e552-e554. PubMed ID: 27640873
    [No Abstract]   [Full Text] [Related]  

  • 17. Lower doses of factor VIII for hemophilia.
    Penner JA; Kelly PE
    N Engl J Med; 1977 Aug; 297(7):401. PubMed ID: 876340
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inhibitors (antibodies) directed against factor VIII in hemophilia A (author's transl)].
    Beck EA
    Ther Umsch; 1979 Apr; 36(4):326-9. PubMed ID: 377556
    [No Abstract]   [Full Text] [Related]  

  • 19. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of acquired factor VIII inhibitors.
    Onitilo AA; Skorupa A; Lal A; Ronish E; Mercier RJ; Islam R; Lazarchick J
    Thromb Haemost; 2006 Jul; 96(1):84-7. PubMed ID: 16807656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.